Company intelligence / Profile preview

mProbe

Palo Alto, California, United Statesmprobe.com ↗

Ownership: Private
Development stage: Other

Overview

mProbe provides advanced molecular diagnostic services using proprietary multiomic platforms integrating artificial intelligence. Their technology enables deep phenotyping of tumors and personalized health risk assessment across several major diseases. They have demonstrated clinical utility in precision oncology by supporting therapy selection through partnerships such as with CureMatch. Their platforms are used commercially for both research and clinical decision support.

Therapeutic areas: NephrologyEndocrinologyOncology
Modalities: Diagnostic platform (multiomic)Artificial intelligence-based diagnosticsProteomics platform (targeted proteomics)Metabolomics platform
Industry: Protein Biomarker Diagnostics

Partnerships

CureMatch

Beyond the preview

Go deeper on mProbe.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on mProbe.

Explore the full profile